During cancer progression, tumor cells overcome the cytostatic effects of TGF‐β signaling, by acquiring mutations in the canonical signaling components, by adaptation of TGF‐β signaling through non‐canonical signaling and by gain of function of proto‐oncogenes or loss of function of tumor suppressor genes. The gene discussed is TGFB1; the disease is cancer.